Fitness selection of hyperfusogenic measles virus F proteins associated with neuropathogenic phenotypes.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
04 05 2021
Historique:
entrez: 27 4 2021
pubmed: 28 4 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Measles virus (MeV) is resurgent and caused >200,000 deaths in 2019. MeV infection can establish a chronic latent infection of the brain that can recrudesce months to years after recovery from the primary infection. Recrudescent MeV leads to fatal subacute sclerosing panencephalitis (SSPE) or measles inclusion body encephalitis (MIBE) as the virus spreads across multiple brain regions. Most clinical isolates of SSPE/MIBE strains show mutations in the fusion (F) gene that result in a hyperfusogenic phenotype in vitro and allow for efficient spread in primary human neurons. Wild-type MeV receptor-binding protein is indispensable for manifesting these mutant F phenotypes, even though neurons lack canonical MeV receptors (CD150/SLAMF1 or nectin-4). How such hyperfusogenic F mutants are selected and whether they confer a fitness advantage for efficient neuronal spread is unresolved. To better understand the fitness landscape that allows for the selection of such hyperfusogenic F mutants, we conducted a screen of ≥3.1 × 10

Identifiants

pubmed: 33903248
pii: 2026027118
doi: 10.1073/pnas.2026027118
pmc: PMC8106313
pii:
doi:

Substances chimiques

Viral Fusion Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI123449
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI115226
Pays : United States

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Virology. 2001 Dec 20;291(2):215-25
pubmed: 11878891
J Pathol. 2015 Jan;235(2):253-65
pubmed: 25294240
Virology. 1980 Aug;105(1):205-22
pubmed: 7414950
Virology. 2015 Aug;482:234-43
pubmed: 25899178
J Virol. 2013 Mar;87(5):2648-59
pubmed: 23255801
Virology. 1992 Jun;188(2):910-5
pubmed: 1585658
Science. 2018 Jan 19;359(6373):290-296
pubmed: 29348231
J Virol. 1998 Feb;72(2):1224-34
pubmed: 9445022
Structure. 2001 Mar 7;9(3):255-66
pubmed: 11286892
Methods. 2016 May 15;101:113-24
pubmed: 26626326
J Infect Dis. 2005 Nov 15;192(10):1686-93
pubmed: 16235165
Viruses. 2016 Apr 21;8(4):112
pubmed: 27110811
Viruses. 2016 Sep 20;8(9):
pubmed: 27657109
J Virol. 2001 May;75(9):4399-401
pubmed: 11287589
J Virol. 2019 Feb 5;93(4):
pubmed: 30487282
Cell. 1988 Oct 21;55(2):255-65
pubmed: 3167982
J Cell Sci. 2019 Aug 23;132(16):
pubmed: 31331966
Sci Immunol. 2019 Nov 1;4(41):
pubmed: 31672862
J Virol. 2010 Nov;84(21):11189-99
pubmed: 20719945
Nat Genet. 2019 Oct;51(10):1475-1485
pubmed: 31548722
Science. 2015 May 8;348(6235):694-9
pubmed: 25954009
J Virol. 1999 Jan;73(1):251-9
pubmed: 9847328
J Virol. 2015 Mar;89(5):2710-7
pubmed: 25520515
J Virol. 2018 Feb 26;92(6):
pubmed: 29298883
MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1700-1705
pubmed: 33180759
Gene Ther. 2013 Mar;20(3):338-47
pubmed: 22717740
Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2496-2501
pubmed: 29463726
Curr Opin Virol. 2014 Apr;5:16-23
pubmed: 24492202
J Virol. 2006 Feb;80(3):1524-36
pubmed: 16415028
Nat Rev Dis Primers. 2016 Jul 14;2:16049
pubmed: 27411684
mSphere. 2017 Mar 29;2(2):
pubmed: 28405630
Genome Biol. 2019 Mar 14;20(1):50
pubmed: 30867008
Arch Virol. 2017 Aug;162(8):2493-2504
pubmed: 28389807
mBio. 2015 Feb 10;6(1):
pubmed: 25670774
Pathog Dis. 2019 Mar 1;77(2):
pubmed: 30985897
Curr Opin Virol. 2014 Apr;5:24-33
pubmed: 24530984
Virology. 2007 May 25;362(1):235-44
pubmed: 17434199
Virus Res. 2002 Jun;86(1-2):123-31
pubmed: 12076836
Viruses. 2020 Jan 30;12(2):
pubmed: 32019182
Trends Microbiol. 2019 Feb;27(2):164-175
pubmed: 30220445
PLoS One. 2013 Jul 09;8(7):e68909
pubmed: 23874807
J Virol. 2011 Nov;85(22):11871-82
pubmed: 21917959
J Virol. 2017 Nov 14;91(23):
pubmed: 28904193
Science. 2019 Nov 1;366(6465):599-606
pubmed: 31672891
Viruses. 2016 Apr 21;8(4):109
pubmed: 27110809
EMBO J. 1998 Jul 15;17(14):3899-908
pubmed: 9670007
Virology. 1992 May;188(1):135-42
pubmed: 1566568
Cell Rep. 2015 Jun 9;11(9):1331-8
pubmed: 26004185

Auteurs

Satoshi Ikegame (S)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.

Takao Hashiguchi (T)

Laboratory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, 606-8507 Kyoto, Japan.
Department of Virology, Faculty of Medicine, Kyushu University, 819-0395 Fukuoka, Japan.

Chuan-Tien Hung (CT)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.

Kristina Dobrindt (K)

Pamela Sklar Division of Psychiatric Genomics, Department of Genetics and Genomics, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.

Kristen J Brennand (KJ)

Pamela Sklar Division of Psychiatric Genomics, Department of Genetics and Genomics, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.

Makoto Takeda (M)

Department of Virology III, National Institute of Infectious Diseases, 162-0052 Tokyo, Japan.

Benhur Lee (B)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029; Benhur.Lee@mssm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH